Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
RENOVIS INC (RNVS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/02/2008 8-K Quarterly results
05/01/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Renovis Stockholders Approve Acquisition by Evotec"
04/25/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "PROXY GOVERNANCE AND EGAN-JONES RECOMMEND RENOVIS SHAREHOLDERS VOTE FOR MERGER WITH EVOTEC"
04/22/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "GLASS LEWIS & CO. RECOMMENDS RENOVIS SHAREHOLDERS VOTE FOR MERGER WITH EVOTEC"
04/18/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "ISS/RISK METRICS RECOMMENDS RENOVIS SHAREHOLDERS VOTE FOR MERGER WITH EVOTEC"
04/03/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Renovis Announces Expiration of Hart-Scott-Rodino 30-Day Waiting Period; Merger with Evotec On Track to Close In Early May, 2008 South San Francisco, California - April 3, 2008 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired without the United States Federal Trade Commission requesting additional information with regard to the pending acquisition of Renovis by Evotec AG . The companies anticipate that the transaction, which remains subject to the approval of Renovis's stockholders and other customary closing conditions, will close in earl..."
03/26/2008 8-K Other Events
03/14/2008 8-K Quarterly results
Docs: "RENOVIS REPORTS FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS South San Francisco, California - March 14, 2008 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced financial results for the fourth quarter and year ended December 31, 2007. Revenue for the fourth quarter and the year ended December 31, 2007 was $1.3 million and $9.8 million, respectively, compared to $2.2 million and $10.4 million in the corresponding periods in 2006. All of the revenue earned in the year ended December 31, 2007 related to our collaboration with Pfizer Inc. to research, develop and commercialize small molecules that target the vanilloid receptor, or VR1. The decreas..."
02/05/2008 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/11/2008 8-K Other Events
11/20/2007 8-K Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits
Docs: "Notice to directors and executive officers of Renovis, Inc"
11/07/2007 8-K Quarterly results
Docs: "REGISTRANT'S PRESS RELEASE DATED NOVEMBER 6, 2007"
10/02/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Chairman Agreement, by and between the Company and John P. Walker",
"Form of Deferred Stock Unit Award Grant Notice and Agreement by and between the Company and John P. Walker",
"RENOVIS ANNOUNCES MANAGEMENT CHANGES"
09/24/2007 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
Docs: "Agreement and Plan of Merger, by and between Renovis, Inc. and Evotec AG",
"Amendment to Rights Agreement"
09/19/2007 8-K Asset disposition
08/07/2007 8-K Quarterly results
Docs: "REGISTRANT'S PRESS RELEASE DATED AUGUST 7, 2007"
06/29/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "RENOVIS ANNOUNCES MANAGEMENT CHANGES South San Francisco, California - June 28, 2007 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced the promotions of three key employees to management positions following the resignation of John C. Doyle, Senior Vice President of Corporate Development and Chief Financial Officer, who is leaving the Company to pursue another opportunity. Jeffrey S. Farrow has been promoted to Vice President of Finance and Chief Accounting Officer, and George F. Fraley has been promoted to Vice President of Legal Affairs and will also retain his current title as Associate General Counsel. In addition, Michael C. Ellis, Ph.D., has bee..."
06/11/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "RENOVIS ANNOUNCES ACHIEVEMENT OF MILESTONES IN VR1 COLLABORATION WITH PFIZER INC. South San Francisco, California - June 8, 2007 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced the achievement of two milestones in its research collaboration with Pfizer Inc. to discover and develop VR1 antagonists for the potential treatment of pain and other indications. The milestones include the placement of a second product candidate from the VR1 program into IND-enabling studies as well as completion of certain studies with a previously nominated compound. In addition to triggering aggregate payments of $4.5 million from Pfizer to Renovis, these milestones illu..."
05/08/2007 8-K Quarterly results
Docs: "RENOVIS REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS South San Francisco, California - May 8, 2007 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2007. Revenue for the quarter ended March 31, 2007 was $1.3 million compared with $2.5 million in the first quarter of 2006. The decrease in revenue resulted primarily from a change in the amortization period for the upfront license payment that Renovis received from Pfizer Inc. in connection with the original VR1 collaboration agreement in 2005. The amortization period was extended following the Company's recent agreement with Pfizer to extend the ..."
04/10/2007 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists South San Francisco, California- April 10, 2007 — Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced an agreement with Pfizer Inc. to extend the term of the companies' worldwide collaboration to research, develop and commercialize small molecules that target the vanilloid receptor, VR1. This extension provides Renovis with additional research funding through June 30, 2008 and reflects the goal of Pfizer and Renovis to advance multiple, small molecule VR1 antagonists toward clinical development. The VR1 receptor is a member of a related group of ion channel protei..."
03/01/2007 8-K Quarterly results
Docs: "REGISTRANTS'S PRESS RELEASE DATED MARCH 1, 2007"
02/01/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Employment Agreement by and between the Company and Corey S. Goodman, Ph.D., datedJanuary 30, 2007",
"Form of Amended and Restated Employment Agreement by and between the Company and Executive Officer",
"Form of Deferred Stock Unit Award Grant Notice and Agreement by and between the Company and officers",
"Form of Deferred Stock Unit Award Grant Notice and Agreement by and between the Company and employees"
01/23/2007 8-K Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits
Docs: "Renovis Restructures to Focus on Advancing its Neurological and Inflammatory Disease Programs into Clinical Trials"
01/08/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Stock Option Cancellation Agreement"
01/04/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Confidential Separation Agreement between Renovis, Inc. and Tito A. Serafini, Ph.D",
"Renovis, Inc. 2007 Employment Commencement Incentive Plan",
"Form of Stock Option Agreement under the Renovis, Inc. 2007 Employment Commencement Incentive Plan",
"Renovis Announces Management Changes"
10/26/2006 8-K Quarterly results
Docs: "RENOVIS REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS",
"NXY-059 Does Not Meet Efficacy Endpoints in Phase III Trial for Acute Ischemic Stroke"
09/15/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amended and Restated Employment Agreement by and between the Company and Corey S. Goodman, Ph.D.",
"Form of Amended and Restated Employment Agreement by and between the Company and Executive Officer"
07/27/2006 8-K Quarterly results
Docs: "RENOVIS REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS"
06/12/2006 8-K Other Events, Financial Statements and Exhibits
Docs: "Renovis Updates Progress of Pivotal SAINT II Trial with NXY-059"
06/02/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Transition and Separation Agreement by and between the Company and Dushyant Pathak, Ph.D., effective as of May 31, 2006"
05/18/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Renovis Names Donald R. Joseph as Senior Vice President, Corporate Development and General Counsel"
04/28/2006 8-K Quarterly results
Docs: "RENOVIS REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS South San Francisco, California - April 27, 2005 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for diseases and disorders in the areas of cytoprotection, pain and inflammation, today announced financial results for the first quarter ended March 31, 2006. Revenue for the quarter ended March 31, 2006 was $2.5 million, which included $2.2 million from our collaboration with Pfizer Inc to discover and develop VR1 antagonists for pain and other indications. This compares to first quarter 2005 revenue of $0.7 million from our collaboration with Genentech, Inc. in the areas of neurological disorders and anti-angiogenesis."
02/24/2006 8-K Quarterly results
Docs: "RENOVIS REPORTS FOURTH QUARTER AND FULL YEAR 2005 FINANCIAL RESULTS South San Francisco, California - February 23, 2006 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for diseases and disorders in the areas of neuroprotection, pain and inflammation, today announced financial results for the fourth quarter and year ended December 31, 2005. Revenue for the quarter and year ended December 31, 2005 was $2.6 million and $6.6 million, which included $2.2 million and $4.4 million in revenue, respectively, from our collaboration with Pfizer, Inc. to discover and develop VR1 antagonists for pain and other indications. The remainder of our revenue during these periods as well as our total revenue of $0.7 million and $2.6 million for the quarter and ye..."
02/09/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Renovis, Inc. 2006 Employment Commencement Incentive Plan",
"Form of Stock Option Agreement under the Renovis, Inc. 2006 Employment Commencement Incentive Plan"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy